Zhejiang Jingxin Pharmaceutical Co., Ltd.

Zhejiang Jingxin Pharmaceutical Co., Ltd. is a publicly traded pharmaceutical company based in China, listed on the Shenzhen Stock Exchange since 2004. The company specializes in the integration of research and development, production, and sales within the pharmaceutical sector. It operates under the mission of safeguarding health and aims to lead in the fields of mental and neurological health, as well as cardiovascular and cerebrovascular health. The company’s primary business lines include the research, production, and sales of active pharmaceutical ingredients, chemical formulations, traditional Chinese medicine, biologics, and medical devices. Its largest segment is chemical formulations, which address various health conditions, including mental disorders and cardiovascular diseases. Additionally, Zhejiang Jingxin is a significant global manufacturer of quinolone antibacterial active pharmaceutical ingredients. Its wholly-owned subsidiary, BEACON, focuses on medical imaging displays, holding a leading market share in this sector. The company emphasizes a dual strategy of developing both innovative and generic drugs, while continuously enhancing its supply capabilities and market presence.

Integrated active pharmaceutical ingredient-formulation, creating cost advantages, and strengthening supply capabilities: Currently, most of the company's finished products are produced with integrated active pharmaceutical ingredients, and it continuously extends upstream to achieve self-supply of key intermediates. It continuously improves its industrial layout to provide stable supply capabilities for the hospital market after centralized procurement. Guided by market and clinical value, striving for a "combination of innovation and generic drugs" approach: Focusing on mental and neurological health and cardiovascular and cerebrovascular health, the company promotes the simultaneous development of innovative drugs and generic drugs, enriching the product pipeline continuously and providing a source of power for the company's sustainable development. Continuous improvement of service capabilities, driving market upgrades: Leveraging its strong oral solid formulation technology transfer capabilities and high-quality commercial delivery experience, the company actively introduces domestic and foreign formulation outsourcing business to expand growth opportunities for its formulation business. It strengthens the construction of its active pharmaceutical ingredient product access capability, actively expands the mainstream market, and continuously enhances its international customer's active ingredient supply service capability. BEACON continually improves its research and development, lean manufacturing, and system integration capabilities, building core competitiveness in product capabilities and comprehensive delivery capabilities. Balancing in-hospital and out-of-hospital, persisting in building marketing capabilities: As healthcare reform continues to deepen and centralized procurement policies advance, the company actively responds to market changes, strengthens the top-level design of its sales architecture, establishes two major business units—hospitals and retail, and bases itself in hospitals while expanding outside hospitals. It promotes multi-channel coordinated development and advances marketing capability construction and enhancement.